Regencell Bioscience Holdings Limited Ordinary Shares RGC

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

RGC hizo una división de acciones (split) de 38:1 el 16 de junio de 2025: cada acción se convirtió en 38. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 22 jun

  DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

  Class action lawsuits have been filed against LKQ Corporation, Regencell Bioscience Holdings Limited, and Globant S.A. The complaints allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their businesses. LKQ faced issues with FinishMaster losing major customers post-acquisition, Regencell was vulnerable to market manipulation, and Globant faced decreasing demand in Latin America with frozen wages.

  

• GlobeNewswire Inc. 21 jun

  FSK DEADLINE NOTICE: ROSEN, A RANKED AND LEADING FIRM, Encourages FS KKR Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FSK

  Rosen Law Firm has announced securities class action lawsuits against FS KKR Capital Corp. (FSK), Regencell Bioscience Holdings Limited (RGC), and Microsoft (MSFT). The FSK lawsuit alleges the company made false statements regarding portfolio restructuring effectiveness, investment valuations, and distribution strategy durability. Investors with losses exceeding $100K are encouraged to join the class action before the July 6, 2026 deadline for FSK and June 23, 2026 for RGC.

  

• GlobeNewswire Inc. 21 jun

  REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC

  Rosen Law Firm is encouraging investors with losses exceeding $100,000 in Regencell Bioscience Holdings Limited, FS KKR Capital Corp., and Microsoft to join securities class action lawsuits. The firm has set a June 23, 2026 deadline for lead plaintiff claims. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities and regulatory risks.

  

• GlobeNewswire Inc. 20 jun

  RGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

  Faruqi & Faruqi, LLP is reminding investors in Regencell Bioscience Holdings Limited (RGC) of the June 23, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Regencell and its executives made false and misleading statements by concealing the company's vulnerability to market manipulation and the resulting regulatory risks. The DOJ investigation was disclosed on October 31, 2025, causing RGC's share price to fall 18.56% on November 3, 2025.

  

• GlobeNewswire Inc. 18 jun

  SRAD IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sportradar Group AG Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - SRAD

  Rosen Law Firm has issued multiple securities class action deadline alerts for investors. The primary case involves Sportradar Group AG (SRAD), where investors who purchased shares between November 7, 2024 and April 21, 2026 may be entitled to compensation. The lawsuit alleges that Sportradar made false statements about compliance and worked with black-market gambling operators while claiming strict regulatory adherence. The lead plaintiff deadline is July 17, 2026. Similar deadline alerts were also issued for FS KKR Capital Corp. (FSK) and Regencell Bioscience Holdings Limited (RGC).